Agenus Announces Agenus Insights - Virtual R&D Miniseries
February 09 2021 - 11:00AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced that it will host its
inaugural
Agenus Insights on “Optimally
Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m.
ET.
This R&D miniseries, a brief yet concise summary of key
insights into the most impactful areas of research in
immuno-oncology and Agenus’ contributions to them, will include a
15-minute presentation and a 15-minute Q&A session.
S1E1, “Optimally Targeting TIGIT,” will be hosted by Dr. Steven
O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific
Director, Head of Drug Discovery.
The webinar will begin with a fast-paced discussion by Dr.
Steven O’Day and Dr. Dhan Chan highlighting the clinical validation
of TIGIT as an anti-cancer target and the rationale for Agenus’
Fc-enhanced design. The remainder of the webinar will be made
available for a Q&A session.
Registration for the webinar can be done in advance at
https://agenusbio.zoom.us/webinar/register/WN_tOrL5VCkRoSh7lFKqOCKAA.
A replay will be available after the webinar on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter
handle @agenus_bio. Information that may be important to investors
will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding TIGIT. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Contact:Agenus
Inc. Caroline
Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024